Sponsor of the Day:
Jerkmate
https://www.biopharmadive.com/news/intellia-crispr-hereditary-angioedema-results-nejm/730876/
Intellia data spark debate about CRISPR drug’s potential | BioPharma Dive
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't silence questions about its...
spark debatebiopharma diveintelliadatacrispr
https://www.intelliatx.com/patient-stories/milton-living-with-attr-cm/
Milton | Living with ATTR Amyloidosis with Cardiomyopathy - Intellia Therapeutics
Dec 19, 2025 - Milton recently celebrated his 60th birthday, a personal milestone, and a moment to reflect on his life and those he loves dearest.
attr amyloidosisintellia therapeuticsmiltonlivingcardiomyopathy
https://www.it-boltwise.de/intellias-crispr-therapie-zeigt-vielversprechende-ergebnisse-bei-seltenen-erkrankungen.html
Intellia's CRISPR-Therapie zeigt vielversprechende Ergebnisse bei seltenen Erkrankungen
Intellia's CRISPR-Therapie lonvo-z zeigt in Phase-3-Studie signifikante Reduktion von Schwellungsattacken bei HAE-Patienten.
bei seltenen erkrankungenintelliacrisprtherapiezeigt
https://www.statnews.com/pharmalot/2026/04/27/lilly-deal-intellia-crispr-treatment-for-rare-disease/
Pharmalittle: Lilly buying Ajax, Intellia reports HAE CRISPR results | STAT
Apr 27, 2026 - A pill for hair loss successfully spurred hair growth in a late-stage trial amid a surge of investor enthusiasm for such products
results statpharmalittlelillybuyingajax
https://www.fool.com/quote/nasdaq/ntla/
Intellia Therapeutics - NTLA - Stock Price & News | The Motley Fool
stock price newsintellia therapeuticsmotley fool
https://www.intelliatx.com/
Intellia Therapeutics - Revolutionize the course of medicine
Apr 27, 2026 - Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based...
intellia therapeuticsrevolutionizecoursemedicine
https://www.intelliatx.com/about/
About - Intellia Therapeutics
Feb 25, 2026 - Learn more about Intellia, a clinical-stage genome editing company, developing novel, potentially curative therapeutics using CRISPR.
intellia therapeutics
https://www.intelliatx.com/our-science/?sid=crispr-videos
Our Science - Intellia Therapeutics
Feb 23, 2026 - Intellia is investigating CRISPR for gene editing, a new way to make changes to DNA to potentially treat genetic disease. Learn more.
intellia therapeuticsscience
https://www.biospace.com/fda/life-threatening-liver-toxicity-triggers-fda-freeze-on-two-intellia-gene-therapy-studies
Life-Threatening Liver Toxicity Triggers FDA Freeze on Two Intellia Gene Therapy Studies - BioSpace
Oct 30, 2025 - The clinical hold comes days after Intellia voluntarily paused enrollment and dosing in the same two studies.
life threateninggene therapylivertoxicitytriggers
https://www.biopharmadive.com/news/intellia-gene-editing-hereditary-angioedema-lonvo-z-results/818503/
Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder | BioPharma Dive
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of...
late stagebiopharma diveintelliacrisprdrug